stockportfolio.pro
DXCM vs RPRX: Which Stock Is the Better Buy?
DexCom, Inc. and Royalty Pharma plc side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — DXCM vs RPRX, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| DexCom, Inc. (DXCM) | Royalty Pharma plc (RPRX) | |
|---|---|---|
| Market cap | $29.6B | $31.6B |
| Revenue (latest FY) | $4.66B | $2.38B |
| Net income (latest FY) | $836.30M | $770.95M |
| Revenue growth (5y CAGR) | 19.3% | 2.3% |
| Net margin | 17.9% | 32.4% |
| Return on equity | 30.5% | 11.9% |
| P/E ratio | 32.9 | 28.9 |
| Dividend yield | — | 1.7% |
| Profitable years (of last 10) | 7 | 8 |
| Positive free cash flow | Yes | — |
See the full DXCM vs RPRX breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open DXCM's full financials → Open RPRX's full financials →More comparisons
Frequently asked questions
Which is bigger, DXCM or RPRX?
Royalty Pharma plc is larger by market capitalization — $31.6B versus $29.6B.
Which grows faster, DXCM or RPRX?
Over the last five fiscal years, DexCom, Inc. grew revenue faster — 19.3%/yr versus 2.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.